Historical Valuation
Aurinia Pharmaceuticals Inc (AUPH) is now in the Fair zone, suggesting that its current forward PS ratio of 6.59 is considered Fairly compared with the five-year average of 3.48. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between 11.47 to 45.38 according to relative valuation methord.
Relative Value
Fair Zone
11.47-45.38
Current Price：16.02
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Aurinia Pharmaceuticals Inc (AUPH) has a current Price-to-Book (P/B) ratio of 5.53. Compared to its 3-year average P/B ratio of 3.29 , the current P/B ratio is approximately 68.30% higher. Relative to its 5-year average P/B ratio of 3.90, the current P/B ratio is about 41.99% higher. Aurinia Pharmaceuticals Inc (AUPH) has a Forward Free Cash Flow (FCF) yield of approximately 5.91%. Compared to its 3-year average FCF yield of -0.04%, the current FCF yield is approximately -14433.72% lower. Relative to its 5-year average FCF yield of -3.38% , the current FCF yield is about -274.96% lower.
P/B
Median3y
3.29
Median5y
3.90
FCF Yield
Median3y
-0.04
Median5y
-3.38
Competitors Valuation Multiple
AI Analysis for AUPH
The average P/S ratio for AUPH competitors is 16.86, providing a benchmark for relative valuation. Aurinia Pharmaceuticals Inc Corp (AUPH.O) exhibits a P/S ratio of 6.59, which is -60.88% above the industry average. Given its robust revenue growth of 8.41%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AUPH
1Y
3Y
5Y
Market capitalization of AUPH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AUPH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AUPH currently overvalued or undervalued?
Aurinia Pharmaceuticals Inc (AUPH) is now in the Fair zone, suggesting that its current forward PS ratio of 6.59 is considered Fairly compared with the five-year average of 3.48. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between 11.47 to 45.38 according to relative valuation methord.
What is Aurinia Pharmaceuticals Inc (AUPH) fair value?
AUPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between 11.47 to 45.38 according to relative valuation methord.
How does AUPH's valuation metrics compare to the industry average?
The average P/S ratio for AUPH's competitors is 16.86, providing a benchmark for relative valuation. Aurinia Pharmaceuticals Inc Corp (AUPH) exhibits a P/S ratio of 6.59, which is -60.88% above the industry average. Given its robust revenue growth of 8.41%, this premium appears unsustainable.
What is the current P/B ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Jan 09 2026?
As of Jan 09 2026, Aurinia Pharmaceuticals Inc (AUPH) has a P/B ratio of 5.53. This indicates that the market values AUPH at 5.53 times its book value.
What is the current FCF Yield for Aurinia Pharmaceuticals Inc (AUPH) as of Jan 09 2026?
As of Jan 09 2026, Aurinia Pharmaceuticals Inc (AUPH) has a FCF Yield of 5.91%. This means that for every dollar of Aurinia Pharmaceuticals Inc’s market capitalization, the company generates 5.91 cents in free cash flow.
What is the current Forward P/E ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Jan 09 2026?
As of Jan 09 2026, Aurinia Pharmaceuticals Inc (AUPH) has a Forward P/E ratio of 18.95. This means the market is willing to pay $18.95 for every dollar of Aurinia Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Jan 09 2026?
As of Jan 09 2026, Aurinia Pharmaceuticals Inc (AUPH) has a Forward P/S ratio of 6.59. This means the market is valuing AUPH at $6.59 for every dollar of expected revenue over the next 12 months.